Mersana Q1 net loss $19.3M ($0.16/shr); XMT-1660 Phase 1 ongoing, XMT-2056 resumed

Mersana Therapeutics, Inc.

2024-Q1 EPS reported -$0.16 revenue$9,245,000

Net loss of $19.3M ($0.16/shr) vs $56.2M loss ($0.52) in Q1 2023; collaboration revenue $9.2M (up from $7.8M).
Cash, equivalents and securities $183.1M; expects runway into 2026.
XMT-1660 Phase 1 dose escalation continues; MTD not yet reached; initial data and expansion expected H2 2024.
XMT-2056 Phase 1 resumed enrollment after clinical hold lifted; dose escalation planned in 2024.
R&D expenses fell sharply to $18.7M from $47.3M driven by UpRi discontinuation and restructuring.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Mersana Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $9.2 million, net income $19.3 million net loss, EPS $0.16 per share.

Period: first quarter ended March 31, 2024
Revenue: $9.2 million
Net income: $19.3 million net loss
EPS: $0.16 per share
Result: reported results

Exact text from the filing

plan commitments into 2026. ● Net cash used in operating activities for the first quarter of 2024 was $32.7 million. · Collaboration revenue for the first quarter of 2024 was $9.2 million, compared to $7.8 million for the same period in 2023. The year-over-year change was primarily related to the company’s Johnson & Johnson collaboration, including both research

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001104659-24-059104

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.